Impact News +++ ANLEIHEN-Woche #KW34 – 2025: Energiekontor, JDC, The Platform Group, Aream, LEEF, Dt. Rohstoff,... (Anleihen-Finder) +++ PLATFORM GROUP Aktie +4,84%

INOVIO Aktie

>INOVIO Aktienkurs

1.72 EUR +4.2% (Tradegate)

Ask: 1.71 EUR / 1749 Stück

Bid: 1.64 EUR / 1830 Stück

Tagesumsatz: 1129 Stück

Realtime Kurs von 8 bis 22 Uhr!

INOVIO Aktie über LYNX handeln

Intraday

1 Jahr

>INOVIO Performance

1 Woche: +20,1%

1 Monat: +33,1%

3 Monate: -11,0%

6 Monate: -26,1%

1 Jahr: -76,6%

laufendes Jahr: -11,0%

>INOVIO Aktie

Name:

INOVIO PHARMACEUTICAL INC

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US45773H4092 / A400EJ

Symbol/ Ticker:

GBM (Frankfurt) / INO (NASDAQ)

Kürzel:

FRA:GBM, ETR:GBM, GBM:GR, NASDAQ:INO

Index:

Webseite:

https://inovio.com/

Profil:

Inovio Pharmaceuticals, Inc. is a biotechnology co..
>Volltext..

Marktkapitalisierung:

88.48 Mio. EUR

Unternehmenswert:

57.18 Mio. EUR

Umsatz:

0.16 Mio. EUR

EBITDA:

-79.66 Mio. EUR

Nettogewinn:

-75.32 Mio. EUR

Gewinn je Aktie:

-2.24 EUR

Schulden:

9.15 Mio. EUR

Liquide Mittel:

20.9 Mio. EUR

Operativer Cashflow:

-81.35 Mio. EUR

Bargeldquote:

1.5

Umsatzwachstum:

-71.99%

Gewinnwachstum:

34.4%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

INOVIO

Letzte Datenerhebung:

22.08.25

>INOVIO Kennzahlen

Aktien/ Unternehmen:

Aktien: 53.14 Mio. St.

Frei handelbar: 99.21%

Leerverk. Aktien: 14.12%

Rückkaufquote: -29.99%

Mitarbeiter: 134

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 296.28%

Bewertung:

KGV: -

KGV lG: -

KUV: 406.69

KBV: 2.44

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -1560.01%

Gewinnmarge: -48131.35%

Operative Marge: -52568.64%

Managementeffizenz:

Gesamtkaprendite: -86.88%

Eigenkaprendite: -140.12%

>INOVIO Peer Group

Es sind 601 Aktien bekannt.

>INOVIO Chart & Kurs - NASDAQ

>INOVIO News

13.08.25 - 21:12	Inovio Cuts Q2 Losses by 27% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

13.08.25 - 18:12	Inovio rises after promising Q2 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.08.25 - 09:30	Inovio aims for BLA submission and FDA file acceptance by year-end 2025 as 3107 data shows sustained surgery reduction (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.08.25 - 22:06	INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
	On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end Completed design verification (DV) testing of CELLECTRA® 5PSP device required for BLA submission and requested rolling submission from US Food and Drug Administration......

05.08.25 - 17:30	Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
	Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

04.08.25 - 22:09	INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025 (PR Newswire)
	PLYMOUTH MEETING, Pa., Aug. 4, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its second quarter......

09.07.25 - 18:03	Inovio wins new Overweight at Piper Sandler on potential FDA nod for lead drug (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.07.25 - 14:03	INOVIO announces pricing of $25M public offering (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.07.25 - 13:33	INOVIO Announces Pricing of $25 Million Public Offering (PR Newswire)
	PLYMOUTH MEETING, Pa., July 3, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the......

03.07.25 - 04:54	INOVIO Pharma Announces Proposed Public Offering (AFX)
	WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof......

02.07.25 - 22:27	Inovio Pharmaceuticals announces proposed public offering of common stock and warrants (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.07.25 - 22:18	INOVIO Announces Proposed Public Offering (PR Newswire)
	PLYMOUTH MEETING, Pa., July 2, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that......

14.05.25 - 01:09	Inovio outlines BLA submission timeline for INO-3107 and reports $68.4M cash position while advancing DNA medicine pipeline (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.25 - 01:00	Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
	Inovio (INO) delivered earnings and revenue surprises of 31.08% and 30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...

13.05.25 - 22:27	Earnings Snapshot: INOVIO says current cash pile enough to support ops till Q1 2026 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.05.25 - 22:12	Inovio Pharmaceuticals GAAP EPS of -$0.51 beats by $0.23 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.05.25 - 22:09	INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
	On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025 Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated......

30.04.25 - 14:09	INOVIO to Present at Upcoming Scientific and Investor Conferences (PR Newswire)
	PLYMOUTH MEETING, Pa., April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be......

29.04.25 - 14:09	INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025 (PR Newswire)
	PLYMOUTH MEETING, Pa., April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter......

21.04.25 - 15:00	Bet on These 5 Top-Ranked Stocks With Rising P/E (Zacks)
	Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das nackte Kind, das zagt nicht; mit seinem Pfennig springt es fort und kennt recht gut den Sammelort - ich meine des Bäckers Laden. - Johann Wolfgang von Goethe

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram